In a cohort of 86 patients with r/r AML retrospectively analyzed by Stahl and colleagues, NPM1 mutations predicted higher response rates to VEN-based combination therapies [100] in line with results from DiNardo et al. [91]. The gene discussed is NPM1; the disease is acute myeloid leukemia.